QURE - uniQure rises as CSL completes licensing deal for hemophilia gene therapy

CSL Behring, a subsidiary of CSL Limited ([[CSLLY]]) has completed the previously announced commercialization and license agreement with uniQure ([[QURE]] +4.7%) for etranacogene dezaparvovec (AMT-061), a gene therapy candidate targeting hemophilia B.The closing of the deal follows the conclusion of antitrust reviews in the US, the UK, and Australia, CSL Behring said.Per the terms of the agreement, uniQure is entitled to an upfront cash payment of $450M in addition to milestone payments and royalties.uniQure is required to complete the Phase 3 HOPE-B trial in hemophilia B and expand the manufacture of the treatment for initial commercial supply.Last month, uniQure announced that the top-line 52-week data from the pivotal HOPE-B trial are likely by the end of Q2 2021.

For further details see:

uniQure rises as CSL completes licensing deal for hemophilia gene therapy